13.76 USD
+1.23 (+9.82%)
At close: Feb 6, 2026
13.7532 USD
-0.01 (-0.05%)
After Hours: 2/6/2026, 8:12:17 PM
We assign a fundamental rating of 4 out of 10 to XRAY. XRAY was compared to 186 industry peers in the Health Care Equipment & Supplies industry. While XRAY is still in line with the averages on profitability rating, there are concerns on its financial health. XRAY has a valuation in line with the averages, but on the other hand it scores bad on growth. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- XRAY had positive earnings in the past year.
- In the past year XRAY had a positive cash flow from operations.
- XRAY had negative earnings in 4 of the past 5 years.
- XRAY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of XRAY (-15.60%) is comparable to the rest of the industry.
- XRAY has a Return On Equity (-59.68%) which is in line with its industry peers.
- XRAY's Return On Invested Capital of 5.04% is fine compared to the rest of the industry. XRAY outperforms 76.88% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for XRAY is below the industry average of 8.80%.
- The last Return On Invested Capital (5.04%) for XRAY is above the 3 year average (4.11%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROIC | 5.04% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
- XRAY's Operating Margin of 7.48% is fine compared to the rest of the industry. XRAY outperforms 74.73% of its industry peers.
- In the last couple of years the Operating Margin of XRAY has declined.
- XRAY has a Gross Margin (51.10%) which is in line with its industry peers.
- XRAY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XRAY is destroying value.
- Compared to 1 year ago, XRAY has less shares outstanding
- Compared to 5 years ago, XRAY has less shares outstanding
- The debt/assets ratio for XRAY is higher compared to a year ago.
2.2 Solvency
- XRAY has an Altman-Z score of 0.99. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.99, XRAY is in line with its industry, outperforming 52.15% of the companies in the same industry.
- The Debt to FCF ratio of XRAY is 29.94, which is on the high side as it means it would take XRAY, 29.94 years of fcf income to pay off all of its debts.
- XRAY's Debt to FCF ratio of 29.94 is fine compared to the rest of the industry. XRAY outperforms 68.28% of its industry peers.
- XRAY has a Debt/Equity ratio of 1.36. This is a high value indicating a heavy dependency on external financing.
- XRAY has a Debt to Equity ratio of 1.36. This is in the lower half of the industry: XRAY underperforms 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Altman-Z | 0.99 |
ROIC/WACC0.57
WACC8.91%
2.3 Liquidity
- XRAY has a Current Ratio of 1.47. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
- XRAY's Current ratio of 1.47 is on the low side compared to the rest of the industry. XRAY is outperformed by 74.19% of its industry peers.
- XRAY has a Quick Ratio of 1.47. This is a bad value and indicates that XRAY is not financially healthy enough and could expect problems in meeting its short term obligations.
- XRAY has a worse Quick ratio (0.99) than 74.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
- The earnings per share for XRAY have decreased strongly by -14.59% in the last year.
- Measured over the past years, XRAY shows a decrease in Earnings Per Share. The EPS has been decreasing by -7.38% on average per year.
- XRAY shows a decrease in Revenue. In the last year, the revenue decreased by -7.08%.
- The Revenue has been decreasing by -1.17% on average over the past years.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
3.2 Future
- The Earnings Per Share is expected to grow by 7.40% on average over the next years.
- XRAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.34% yearly.
EPS Next Y-2.05%
EPS Next 2Y-3.44%
EPS Next 3Y1.79%
EPS Next 5Y7.4%
Revenue Next Year-4.27%
Revenue Next 2Y-1.83%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.34%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 8.71, the valuation of XRAY can be described as very reasonable.
- Compared to the rest of the industry, the Price/Earnings ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.77% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of XRAY to the average of the S&P500 Index (27.93), we can say XRAY is valued rather cheaply.
- The Price/Forward Earnings ratio is 8.84, which indicates a very decent valuation of XRAY.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 97.31% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of XRAY to the average of the S&P500 Index (27.77), we can say XRAY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.71 | ||
| Fwd PE | 8.84 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 95.70% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of XRAY indicates a somewhat cheap valuation: XRAY is cheaper than 77.96% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.32 | ||
| EV/EBITDA | 7.73 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.44%
EPS Next 3Y1.79%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 5.17%, XRAY is a good candidate for dividend investing.
- Compared to an average industry Dividend Yield of 0.20, XRAY pays a better dividend. On top of this XRAY pays more dividend than 99.46% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.81, XRAY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.17% |
5.2 History
- On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
- XRAY has paid a dividend for at least 10 years, which is a reliable track record.
- XRAY has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
- The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
- The dividend of XRAY is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP-14.4%
EPS Next 2Y-3.44%
EPS Next 3Y1.79%
13.76
+1.23 (+9.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners107.4%
Inst Owner Change-0.9%
Ins Owners0.24%
Ins Owner Change-1.58%
Market Cap2.75B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts68.18
Price Target13.01 (-5.45%)
Short Float %7.41%
Short Ratio3.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.17% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)1.71%
PT rev (3m)-19.68%
EPS NQ rev (1m)0.15%
EPS NQ rev (3m)-15.22%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-14.61%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)-0.28%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.71 | ||
| Fwd PE | 8.84 | ||
| P/S | 0.76 | ||
| P/FCF | 34.32 | ||
| P/OCF | 12.42 | ||
| P/B | 1.86 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.73 |
EPS(TTM)1.58
EY11.48%
EPS(NY)1.56
Fwd EY11.32%
FCF(TTM)0.4
FCFY2.91%
OCF(TTM)1.11
OCFY8.05%
SpS18.16
BVpS7.41
TBVpS-4.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROCE | 6.38% | ||
| ROIC | 5.04% | ||
| ROICexc | 5.51% | ||
| ROICexgc | 13.81% | ||
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% | ||
| FCFM | 2.21% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Debt/EBITDA | 3.26 | ||
| Cap/Depr | 40.63% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 0.99 |
F-Score4
WACC8.91%
ROIC/WACC0.57
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y-2.05%
EPS Next 2Y-3.44%
EPS Next 3Y1.79%
EPS Next 5Y7.4%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.27%
Revenue Next 2Y-1.83%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.34%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year42.48%
EBIT Next 3Y13.79%
EBIT Next 5Y11.96%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%
DENTSPLY SIRONA INC / XRAY FAQ
What is the ChartMill fundamental rating of DENTSPLY SIRONA INC (XRAY) stock?
ChartMill assigns a fundamental rating of 4 / 10 to XRAY.
What is the valuation status for XRAY stock?
ChartMill assigns a valuation rating of 6 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Fairly Valued.
How profitable is DENTSPLY SIRONA INC (XRAY) stock?
DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for XRAY stock?
The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 8.71 and the Price/Book (PB) ratio is 1.86.
Can you provide the dividend sustainability for XRAY stock?
The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -14.4%.